Sunshine Biopharma Announces Extension of The Term of Its Brokered Up To $10 Million Private Placement Financing

MONTREAL, QB / ACCESSWIRE / May 10, 2018 / Sunshine Biopharma, Inc. SBFM, a pharmaceutical company focused on the research, development, and commercialization of drugs for the treatment of cancer and other acute and chronic indications, today announced that it has signed an agreement with Jitney Trade Inc. whereby the parties have agreed to extend the equity financing that was previously announced of up to $10,000,000 Canadian (approximately $8,000,000 US) (the "Offering") until August 31, 2018. The terms and conditions of the Offering remained at 400,000,000 shares of the Company's Common Stock at a price of $0.025 Canadian (approximately $0.02 US) per share.

The net proceeds from the Offering will be used for implementation of the Company's business plan including expansion of Generic Pharmaceuticals operations as well as the Analytical Chemistry Services operations of the Company's newly acquired subsidiary, Atlas Pharma Inc. (www.atlaspharmainc.ca). However, the bulk of the proceeds are intended to be used for the Clinical Development of the Company's flagship anti-cancer compound, Adva-27a. The preclinical tests conducted on Adva-27a have demonstrated the drug's effectiveness at destroying multidrug resistant cancer cells including Pancreatic Cancer cells, Invasive Breast Cancer cells, Uterine Sarcoma cells and Small-Cell Lung Cancer cells. Clinical trials for Pancreatic Cancer indication are planned to be conducted at McGill University's Jewish General Hospital in Montreal, Canada.

Safe Harbor Forward-Looking Statements

To the extent that statements in this press release are not strictly historical, including statements as to revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future financial conditions, future collaboration agreements, the success of the Company's development, events conditioned on stockholder or other approval, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made.

For Additional Information Contact:

Camille Sebaaly,
CFO Sunshine Biopharma Inc.
Direct Line: 514-814-0464
camille.sebaaly@sunshinebiopharma.com
www.sunshinebiopharma.com

SOURCE: Sunshine Biopharma, Inc.